Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ganaxolone added to standard of care in refractory status epilepticus
2022-502540-12-00Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Nov 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in status epilepticus (SE) comparing Ganaxolone + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Composite seizure cessation and no escalation within 36 hours and Safety. Started Nov 2023; status: completed.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on 2022-502540-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502540-12-00.